Answers are grounded in this paper and cite their sources.
PURPOSE: The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety. All patients in the extended follow-up provided their written informed consent (data cutoff: December 31, 2016). No new safety signals were observed. CONCLUSION: Rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS, but not OS, benefit over observation.
No takes yet. Share an insight, caveat, or question.
Bachy et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: